Vanda Pharmaceuticals Q3'26 Results Due October 28
Vanda Pharmaceuticals is scheduled to report Q3'26 results after the market closes on October 28. Revenue is estimated at 69.20 million USD and EPS at (0.68) USD.
Related stories
LSEG IBES Sees European Q3 Revenue Growth at 13.6%
The estimate is up from 13.3% a week ago.
M impact | EQUITY | Oct 29, 2026, 02:56 PM UTC
Alphabet Shares Fall 11% as Cloud Growth Fails to Offset Weaker Results
Alphabet shares fell sharply as rapid growth in Google Cloud’s AI segment failed to offset disappointing results elsewhere in the business. The company is pursuing a data-center bu
M impact | EQUITY | Oct 29, 2026, 02:56 PM UTC
European Q3 earnings growth forecast rises to 23.6%
LSEG IBES data puts expected Q3 earnings growth at 23.6%, versus 21.9% a week ago.
M impact | EQUITY | Oct 29, 2026, 02:56 PM UTC
Siniora Food Industries Reports Q3 Profit of 3.5 Million Dinars
M impact | EQUITY | Oct 29, 2026, 02:54 PM UTC
Barksdale Resources Raises CA$15.7 Million in Private Placement
Barksdale Resources closed the final tranche of its private placement, raising CA$15.7 million.
M impact | EQUITY | Oct 29, 2026, 02:54 PM UTC
Reliance Power Shares Gain 9.22%, Remain Down 59% in a Year
Reliance Power shares ended Thursday up 9.22%, while remaining 59% below their year-ago level.
M impact | EQUITY | Oct 29, 2026, 02:54 PM UTC